Turkey: Healthcare PPP Projects: Funders' Direct Agreements


Funders' Direct Agreements ("FDAs") are gaining greater recognition, especially with the introduction of public-private partnership ("PPP") models in healthcare projects in Turkey. In PPP projects, FDAs are significant as they are the only agreement wherein both the third party, which is the Ministry of Finance of Turkey ("Administration" or "MoH") for the purpose of this Newsletter and the lenders are counterparties. Lenders would obtain more protection from the Administration, and would, therefore, be able to overcome certain obstacles through certain mechanisms incorporated under FDAs.

In this article, we will analyze the background and significance of FDAs, the nature of FDAs under Turkish legislation, and the structure and content of the provisions of FDAs. We will also discuss certain provisions of the FDAs, such as step in rights.

Background and Significance of FDAs

The framework of the healthcare PPP projects in Turkey originates from the structure of the private finance initiative method in United Kingdom. Through the introduction of the PPP model in the Turkish healthcare sector, the Administration aim to bring private sector techniques and skills into public services. Such models are structured under project agreements so as to attract lenders, and to provide the opportunity to the project company to obtain financing.

FDA, which is also referred to as lender's direct agreement, is a tripartite agreement to be entered into by and between (i) the project company, which is the special purpose vehicle incorporated by the successful bidder of the tender for the healthcare PPP project in Turkey, (ii) the lender(s), who will be providing financing for the PPP project, or the agent of the lenders of a syndicated loan, and (iii) the MoH as the administration in healthcare PPP projects in Turkey.

The main reason to execute an FDA in a PPP project is to protect the lenders from their losses, when the project company fails to fulfill its key obligations under the project, or when the termination of the project agreement is threatened. It could be ascertained from the reasoning of the Law on Construction and Renewal of and Obtaining Service for Facilities by Public-Private Partnership Models by the MoH and Amendments to Certain Laws and Decrees with the Force of Law1 ("PPP Law") that it is one of the intentions of the PPP Law to improve the bankability of PPP projects.

In Turkish healthcare PPP projects, the project company grants a full security pack, which particularly comprises mortgage over the usufruct right, transfer of receivables as a security, account pledge, share pledge, etc., to the lenders of the project. As a matter of Turkish law, there exist certain arguments and discussions amongst scholars regarding the effectiveness of certain securities that have not yet been tested before the courts. Therefore, FDAs gain greater standing in the eyes of the lenders as a more substantial security as compared to those granted within the security pack under the project.

Nature of the FDAs under Turkish Legislation

With respect to the healthcare PPP projects, although there is no explicit reference to the execution or the nature of FDAs under the PPP Law, it is set forth under the PPP Law that the Administration and the lenders may agree to change the shareholding structure of the project company under certain conditions once the project company defaults. In this sense, the legislator enables execution of an agreement between the Administration and the lenders of the healthcare PPP project and further opens the door for the lenders to agree on step-in rights. In addition to the above, the legislator adopts a similar approach in energy market. Both the Electricity Market Licensing Regulation2 and Natural Gas Market Licensing Regulation3 incorporate similar provisions that enable the lenders to appoint a suitable substitute investor upon occurrence of certain conditions under the legislation.

Since the PPP Law is silent in terms of the nature of the FDA, the contractual provisions between the parties should be considered in order to determine the nature of the FDAs. The intention of the parties of the FDAs is keep the FDA as an independent and separate agreement apart from the project agreement. As such, the parties tend to achieve that the fate of the validity of the FDA is not dependent on the validity or termination of the project agreement. It should be noted that as of the date of this Newsletter, the independent nature of FDAs have not yet been tested before the courts of Turkey.

The Provisions of FDAs

FDAs, in Turkish healthcare projects, incorporate typical provisions of direct agreements used in other project finance deals. Among the customary provisions of agreements, such as definitions, interpretations of the agreement, severability, confidentiality, notices, governing law, etc., certain provisions deserve mention are as follows in a nutshell:

Consent for the Security

As mentioned above, the project company grants certain securities, which particularly include, among others, a mortgage over the usufruct right granted to the project company by the Administration, transfer of receivables by way of security, etc., to the lenders of the project.

As a matter of Turkish law, as long as the laws, or an agreement, or the nature of the business, do not prevent, then the transfer receivables is, in principle, perfected without obtaining consent of the debtor. However, serving notification to the debtor, as well as the receipt of an acknowledgement from the debtor would, in practice, serve as evidence and prevent any good faith claims of the debtors. Where a project company assigns/transfers its receivables (such as lease payments of the Administration to the project company) from the Administration under the project agreement to the lenders as security for the obligations of the project company under the financing, the consent of the Administration may be obtained under the FDAs.

Notification Requirement

In the event of occurrence of default by the project company, the lenders would require to be notified by the Administration for informational purposes before the Administration terminates the project agreement. The details of such notification would be included by the parties under the FDAs.

Step in Rights

If the lenders would like to have the opportunity to step in upon default of the project company, then lenders would request to insert step in provisions into the FDAs. If the parties would agree granting step in right to the lenders, the lenders would appoint a representative upon occurrence of the default of the project company. In such a case, the appointed representative would jointly undertake, together with the project company, all of the rights and obligations under the project documents, and the Administration would be in contact with the appointed representative instead of the project company. The terms regarding the termination of the project agreement during the term of the step in, and the scope of the liability of the lenders for stepping in, and step out rights would also be agreed upon under the FDAs.

In addition to the above, upon occurrence of certain events (i.e., acceleration of the loan or continuance of the default of the project company during the term of the step in period) the lenders would propose to transfer the rights and the obligations of the project company or the shares of the project company to the proposed new investor. The Administration would decide whether or not the proposed new investor is a suitable substitute investor. If so, the Administration would execute another FDA with the suitable substitute investor and its funders under similar terms and provisions.


FDAs are significant for lenders since (i) they are the only agreements wherein the lenders and the Administration are counterparties, (ii) the lenders are protected for their losses, if the project company fails to fulfill its key obligations under the project, or if termination of the project agreement is threatened, and (iii) FDAs provide substantial securities for lenders as compared to those granted within the security pack under the project. The allegations regarding the stand alone nature of FDAs from the legal fate of the project agreement, and the provisions of the FDAs regulated, accordingly, have not yet been tested by the Turkish courts. The parties may agree under an FDA, among others, the consents of the Administration for the security, step in and step out rights of the lenders and suitable substitute investor provisions.


1 The Law on Construction and Renewal of and Obtaining Service for Facilities with Public-Private Partnership Model by the Administration and Amendments to Certain Laws and Decrees with the Force of Law under Law No. 6428 published in the Official Gazette dated 9 March 2013 and numbered 28582.

2  Electricity Market Licensing Regulation published in the Official Gazette dated 2 November 2013 and numbered 28809.

3  Natural Gas Market Licensing Regulation published in the Official Gazette dated 7 September 2002 and numbered 24869.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions